Price$82.51-0.41 (-0.49%)
01:30 PM07:45 PM
News · 26 weeks45-17%
2026-03-012026-08-23
Mix3190d
- Insider18(58%)
- SEC Filings7(23%)
- Other5(16%)
- Earnings1(3%)
Latest news
25 items- INSIDERChief Executive Officer Quisel John D exercised 33,000 shares at a strike of $13.50 and sold $2,611,982 worth of shares (33,000 units at $79.15) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- INSIDERChief Operating Officer Yu Jonathan Yen-Wen exercised 804 shares at a strike of $13.50 and sold $66,445 worth of shares (804 units at $82.64) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Legal Officer Khara Rahul exercised 5,000 shares at a strike of $14.69 and sold $400,000 worth of shares (5,000 units at $80.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Disc Medicine Inc.SCHEDULE 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
- SECSEC Form 10-Q filed by Disc Medicine Inc.10-Q - Disc Medicine, Inc. (0001816736) (Filer)
- SECDisc Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Disc Medicine, Inc. (0001816736) (Filer)
- PRDisc Medicine Reports Second Quarter 2026 Financial Results and Provides Business UpdateCompleted Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded Access Program (EAP) for bitopertin for eligible erythropoietic protoporphyria (EPP) patientsPresented positive clinical data updates from the RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis and the HELIOS open-label extension trial of bitopertin in EPPCompleted enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera (PV) with initial data expected in Q3 2026 and progressing Phase 1b study of DISC-3405 in sickle cell disease (SCD) with initial data
- INSIDERChief Executive Officer Quisel John D exercised 33,000 shares at a strike of $10.68 and sold $2,473,780 worth of shares (33,000 units at $74.96) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- INSIDERChief Operating Officer Yu Jonathan Yen-Wen exercised 100 shares at a strike of $13.50 and sold $8,250 worth of shares (100 units at $82.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Legal Officer Khara Rahul exercised 2,500 shares at a strike of $14.69 and sold $187,500 worth of shares (2,500 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Operating Officer Yu Jonathan Yen-Wen sold $21,750 worth of shares (300 units at $72.50) as part of a pre-agreed trading plan and exercised 300 shares at a strike of $13.50 (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECDisc Medicine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - Disc Medicine, Inc. (0001816736) (Filer)
- INSIDERChief Operating Officer Yu Jonathan Yen-Wen exercised 9,700 shares at a strike of $13.50 and sold $704,795 worth of shares (9,700 units at $72.66) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECDisc Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Disc Medicine, Inc. (0001816736) (Filer)
- INSIDERChief Legal Officer Khara Rahul exercised 7,500 shares at a strike of $14.69 and sold $526,661 worth of shares (7,500 units at $70.22) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Executive Officer Quisel John D exercised 34,000 shares at a strike of $9.86 and sold $2,387,296 worth of shares (34,000 units at $70.21) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director White William Richard4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Ratcliffe Liam4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Nicholson Donald William4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Gemayel Georges4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Chin Mark4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Bitterman Kevin4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Ahmed Nadim4 - Disc Medicine, Inc. (0001816736) (Issuer)
IRON FAQ
5 questionsWhere does IRON stock trade?
Disc Medicine Inc. (IRON) is listed on NASDAQ.What sector and industry is IRON in?
Disc Medicine Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IRON?
Disc Medicine Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy on 2025-11-03.What companies are similar to IRON?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IRON side-by-side with any of them on Quantisnow.How can I track IRON on Quantisnow?
Quantisnow aggregates Disc Medicine Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRON to receive live email and push alerts on every new disclosure.